Monthly Ozempic Cost Slashed After Trump Deal

Core Viewpoint - Novo Nordisk has reduced the prices of its weight loss drug Wegovy and diabetes treatment Ozempic in response to a deal announced by President Trump aimed at lowering pharmaceutical costs in the U.S. [1] Pricing Changes - The out-of-pocket monthly price for Ozempic and Wegovy has decreased from $499 to $349, with a promotional offer for new cash-paying patients to purchase the two lowest doses for $199 per month for the first two months [2][3] - The highest dose of Ozempic, a 2-milligram injection, will remain priced at $499 per month [3] Competitive Landscape - The new pricing for Ozempic and Wegovy aligns with Eli Lilly's Zepbound, which is also priced at $349 per month for its lowest dosage [3] - Novo Nordisk and Eli Lilly will lower the price Medicare pays for their GLP-1 treatments from up to $1,350 per month to $245 per month [5] Market Impact - The announcement did not affect Novo Nordisk's stock, while Eli Lilly's shares experienced a slight decline of 0.2% [4]